| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442794 | European Journal of Cancer | 2014 | 9 Pages |
Abstract
The efficacy of afatinib was inferior to cetuximab in patients with KRAS wild-type mCRC. In patients with KRAS-mutated tumours, disease control was modest with afatinib. Afatinib had a manageable safety profile.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Tamas Hickish, Jim Cassidy, David Propper, Ian Chau, Stephen Falk, Hugo Ford, Tim Iveson, Michael Braun, Vanessa Potter, Iain R. Macpherson, Helen Finnigan, Chooi Lee, Hilary Jones, Mark Harrison,